AbCellera Biologics (NASDAQ:ABCL) has seen its stock price jump by 64 percent week-on-week, making it the top-performing mid-cap stock in the US market last week, thanks to strong clinical trial results from its drug candidate for hot flashes in menopausal women.
On Friday alone, the stock climbed to its highest price in three years of $11.50 before trimming gains to end the session just up by 3.74 percent at $11.38 apiece.
The overall rally can be primarily attributed to its treatment candidate, ABCL635, which successfully reduced hot flash episodes by 83 percent in 92 enrolled postmenopausal women during a phase 2 trial.
Photo by Tima Miroshnichenko on Pexels
ABCL635 was said to have cut the daily hot flash episodes by 8.8 times, significantly outperforming the 33 percent reduction or 3.5 fewer daily hot flashes in participants in…



